← Patent-cliff monitor small molecule SIVEXTRO TEDIZOLID PHOSPHATE
Loss of exclusivity December 2030 latest FDA-listed patent expiry
Drug detail Brand name SIVEXTRO Active ingredient TEDIZOLID PHOSPHATE Strength 200MG/VIAL Dosage form POWDER Route INTRAVENOUS Modality Small molecule FDA approval June 2014 Marketing status RX
Listed patents Patent Expires Type 8426389 December 2030 substance, product 9624250 February 2030 substance, product 10442829 February 2030 substance 10065947 February 2030 product 9988406 February 2030 product 7816379 June 2028 substance, product 8420676 February 2028 substance, product
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.